CVS Faces Steepening Challenges in Its Pharmacy Benefit Management Business

Senior Equity Analyst

Julie Utterback

Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS aims to be the most customer-centric health company in the United States and has spent over a decade positioning itself as a managed care leader, with the acquisitions of pharmacy benefit manager Caremark (2007), insurance provider Aetna (2018), and healthcare service provider Oak Street (2023) defining its strategic direction. CVS' top-tier retail pharmacy, health insurer, and PBM franchises create the potential to improve health outcomes and even bend the healthcare cost curve for its clients, especially if it can align incentives by owning healthcare service providers, as well.

CVS appears uniquely positioned to improve health outcomes, and we appreciate management's focus on better leveraging its assets through digital and other means to bring a more consumer-centric approach to healthcare, which could provide many benefits. For example, management recently highlighted an observational study that showed when members use both CVS medical and pharmacy benefits, their medical costs decline 3%-6% over a three-year period through factors like fewer hospitalizations and emergency room visits. Driving savings like that would be attractive to many potential clients, like self-funded employers, and CVS' own at-risk operations, like its Medicare Advantage plans, by reducing medical costs. Also, CVS continues to dive further into healthcare services through its HealthHub strategy and recent acquisitions of primary-care assets. We think the relatively high-margin healthcare services business could eventually accelerate CVS' profit growth directly or by reducing long-term costs in its medical and pharmacy benefit businesses. 

With its integrated strategy, management aims to accelerate bottom-line growth to the low double digits on a maintainable basis in the long run, but management has pushed the target date for that back multiple times. Now, we only think that growth rate is possible with significant share repurchases toward the end middle of our explicit 10-year forecast period on mid-single-digit operating profit growth in the long run.

Business Strategy & Outlook

CVS Health earns a narrow economic moat rating from us. As a top-tier medical insurer, pharmacy benefit manager, and pharmacy retailer, we believe CVS possesses enough scale-related cost advantages to generate economic profits for the long run. Even after the late 2018 Aetna merger, which cut into returns on invested capital including goodwill, and its recent healthcare services acquisitions, we estimate that CVS' ROICs should remain above its capital costs throughout our explicit 10-year forecast period. CVS generates profits almost equally among its three major segments, and we see the medical insurance and PBM assets as generally stronger than the retail store chain. 

In medical insurance, we see two moat sources—cost advantage and network effects. An insurer’s cost advantages relate primarily to scale, both broadly and locally. The legacy Aetna operations represent the third-largest insurer that we cover, with about 26 million members, albeit a distant third in our coverage universe behind Elevance and UnitedHealth. With such significant scale in the fragmented health insurance market, we believe CVS benefits from local scale advantages in specific metropolitan markets. Local scale advantages allow for greater negotiating leverage versus service providers than smaller insurers in each community, which contributes to cost advantages in each specific location. Also, when local scale advantages are significant enough, we think CVS’ insurance operations benefit from a network effect. According to the American Medical Association, the share of local insurance markets in the U.S. that were highly concentrated grew to 75% in 2021 from 71% in 2014, with the leaders likely taking share in those markets due to local market dynamics. For example, in communities where CVS already has substantial market share, it can offer lower costs or more benefits per member to existing and potential clients than its peers. If that offering is compelling enough, more employers will be attracted to CVS’ insurance plans in those communities, and local service providers, such as hospitals and physician groups, will have more incentive to join and offer lower prices to CVS’ insurance networks to gain access to its large, growing membership rolls. As CVS’ local market share rises, its negotiating leverage with providers also rises, which can create a virtuous cycle (a network effect) where CVS attracts even more clients and more providers to its insurance network in that area. Overall, these dynamics create barriers to entry for would-be competitors, as compiling an attractively priced provider network in a new geography would be difficult without an established membership pool.

CVS’ Caremark segment provides PBM services and appears competitively advantaged in its own right with a combination of moat sources. The PBM industry has consolidated into three top players—CVS, UnitedHealth, and Cigna—controlling nearly 80% of U.S. prescription volumes on an adjusted basis, and we believe those players built their leadership on previous cost advantages. However, with limited cost advantages over each other, we see evidence of some switching costs (through contracts) and network effects now, although CVS' recent contract losses create some new uncertainty around these moat sources, in our opinion. We believe CVS’ leadership position in its PBM operations should help it generate excess returns over time. We continue to view the fixed-cost leverage associated with processing about 2 billion of the nearly 7 billion adjusted prescriptions filled annually. This consolidation of purchasing power helps CVS extract discounts from drug manufacturers on one end of the transaction and pharmacies on the other end of the transaction, which helps create value for its clients, such as insurance plans and employers, on their pharmacy cost trends. We see some switching costs in this business with contract lengths typically around three years and annual retention rates in the high 90s for all three of the top-tier PBM players. Switching the administrative activities, partner relationships, and pharmacy benefit plan specifications to a new PBM vendor can be time-consuming and onerous, which creates inertia for clients with limited realistic alternatives, in our opinion. However, switching is possible, and the loss of specific clients could constrain the firm's growth eventually, especially as new insurance competitors like Elevance, Amazon, and the Mark Cuban Cost Plus Drug Company taking aim at this market. 

CVS possesses a top-tier position in retail pharmacy stores that appears to have some positive qualities, if not a strong moat. CVS drives significant volumes through over 9,000 pharmacy locations. This large store network is attractive for pharmacy benefit managers when assembling plans to obtain volume-based discounts from pharmaceutical manufacturers, and also assembling convenient retail store locations that would be attractive to an insurance plan members. And while it trails Walgreens’ average revenue per store, CVS’ average store revenue remains significantly higher than most other U.S. pharmacies. Scale allows CVS to leverage fixed costs (such as pharmacist salaries and rent) more effectively than subscale peers, and both CVS and Walgreens continue to steal share from smaller independent pharmacies. CVS, Walgreens, and Walmart also have advantageous relationships with the top U.S. drug distributors, which may give them a mild leg up over other retail pharmacies on generic drug pricing. Beyond that, these retail store locations give CVS a unique asset that it may be able to leverage into destinations for higher-margin healthcare services, like primary care, eventually.

In terms of environmental, social, and governance issues, our narrow-moat view of CVS is informed by an analysis of potential changes to the U.S. healthcare system. The key long-term ESG risk that CVS faces, in our opinion, is how U.S. strives to reach universal, affordable coverage. While some strategies considered in recent years to reach universal coverage included eliminating the private insurance industry, those plans have largely been rejected for more moderate proposals that build on the existing healthcare system and include private insurers even in government-sponsored programs like Medicare and Medicaid. During the next 10 years, we view scenarios where CVS provides medical and pharmaceutical benefits through employers and government-sponsored programs (like Medicare Advantage and Medicaid MCOs) as much more likely than not. And overall, since the 2020 election, the impact of potential policy changes has been limited, and we suspect considered changes in the near term (such as increased regulations on the PBM) will be manageable for CVS.

Narrow

Economic Moat

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Pharmacy Services, Retail or Long-Term Care, Health Care Benefits, and Corporate and Other. The Pharmacy Services segment focuses on the pharmacy benefit management solutions. The Retail or Long-Term Care segment includes the sale of prescription drugs and an assortment of health and wellness products, and general merchandise. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, Medicare Part D prescription drug plan, Medicaid health care management services, and health information technology products and services. The Corporate and Other segment is involved in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The job cuts are part of broader strategic changes at the pharmacy chain, but they will reportedly not impact consumer-facing retail staff. Massive layoffs are coming to CVS.

CVS Health is laying off thousands of employees: What's happening and why

CVS Health Corp (NYSE:CVS) announced on Tuesday that it will reduce its workforce by 5,000 positions in a cost-savings move as the drugstore chain broadens its focus to include more health-care offerings.   A spokesperson said the decision is part of an initiative to reprioritize investments around care delivery and technology and reduce expenses.

CVS Health to slash 5000 jobs as shift into health care continues

The pharmacy chain had about 300,000 employees in the U.S. at the end of last year, according to a securities filing.

CVS to slash 5,000 jobs as company deepens costly health care push

Layoffs continue apace after more than 136,000 employees were cut by major U.S. companies in the first quarter of 2023.

2023 Layoff Tracker: CVS Cuts 5,000 Jobs

CVS is laying off about 5,000 employees in a cost-cutting effort, the pharmacy chain confirmed Tuesday.

CVS is laying off 5,000 workers

The expanded offering supports the early diagnosis and management of Chronic Kidney Disease (CKD), impacting an estimated 37 million U.S. adults, many undiagnosed DALLAS and NEW YORK , Aug. 1, 2023 /PRNewswire/ -- Signify Health, a CVS Health company (NYSE: CVS), today announced the addition of a comprehensive in-home kidney health evaluation to its Diagnostic and Preventive Services offering. The new screenings expand Signify Health's suite of services designed to support the early detection, diagnosis, and management of some of the leading causes of morbidity and mortality among people covered under Medicare Advantage.

Signify Health Launches Chronic Kidney Disease Testing, Expands In-Home Diagnostic and Preventive Services Offering

Earnings will likely come in at about $2.10 on a per-share and adjusted basis, nearly matching the $2.11 consensus estimate.

Higher Costs To Weigh On CVS Health's Q2?

Several hedge funds led by billionaires have bought shares of CVS Health this year. These billionaires likely find CVS Health's valuation attractive.

Why Billionaires Are Loading Up on This Dirt-Cheap Stock

CVS said the jobs affected are primarily corporate positions and it doesn't expect customer-oriented roles to be affected, The Wall Street Journal reported.

CVS to Shed 5,000 Jobs in Cost-Cutting Push Just Months After Acquisitions

CVS Health plans to shed 5,000 jobs across the country in the wake of billions of dollars the retail drugstore giant has spent on healthcare services.

As CVS Adds More Healthcare Services, 5,000 Job Cuts And Restructuring Ahead

CVS Health Corp. will slash about 5,000 jobs in a cost-cutting move, the Wall Street Journal reported Monday night. According to the report, the layoffs are primarily in corporate positions, and the company doesn't expect customer-facing positions in its stores, clinics and pharmacies to be affected.

CVS to cut about 5,000 corporate jobs: report

The healthcare giant wants to trim corporate roles and spending on travel and its use of consultants.

CVS to Shed 5,000 Jobs in Cost-Cutting Push

Cameco

Kraft Heinz

Before markets opened on Monday, SoFi Technologies beat the consensus estimate for its second-quarter per-share loss by a penny and beat the consensus revenue estimate by about 3.2%.

Earnings Previews: Cameco, CVS Health, Kraft Heinz

Agree Realty

Kohl's

NETLease Corporate Real Estate ETF

Realty Income Corp

Walgreens

Net lease REITs have historically been solid performers. Elevated interest rates create some headwinds. So does an elevated likelihood of investment grade tenant credit migration.

Net Lease REITs In A New Era

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

ManpowerGroup

MetLife

Omnicom Group

Pfizer

Philip Morris

Raytheon Technologies

Southern Company

Sysco

Verizon

WestRock

Exxon Mobil

The latest edition of Fortune Magazine revealed 500 of the biggest U.S. companies by revenue. To sniff out the best dividend buys, this month, we focus on 68 industry leaders. Those 68 industry leaders were segmented into 21 business sectors ranging from apparel to transportation. 58 dividend-yielding stocks highlighted those 68 industry leaders and ranged 0.16% to 9.31% in annual yield.

Buy 5 Fortune 500 Industry Leaders In July-August And Watch 4 More

CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CVS Health (CVS) Q2 Earnings Expected to Decline

Advance Auto Parts

American Tower

Crown Castle International

Dollar General

O'Reilly Automotive

Walmart

I began writing on Seeking Alpha because I enjoy writing and because it provided me with an opportunity to share investing ideas and strategies with other like-minded investors. Today I want to continue with my “lessons learned” series. Now, whenever I decide to invest in a stock, business, or direct real estate, I always ask myself “is the thrill of victory worth the agony of defeat?"

Is The Thrill Of Victory Worth The Agony Of Defeat?

Alphabet

Riding Warren Buffett's coattails has been making investors richer for decades. Due to an acquisition a quarter of a century ago, Berkshire Hathaway owns a specialty investment company that's effectively Buffett's "secret" portfolio.

3 Magnificent Stocks Being Added Hand Over Fist to Warren Buffett's Secret Portfolio

CVS Pharmacy exclusive beauty and personal care brand, one+other, puts accessibility at the forefront with inclusively designed self-care tools. WOONSOCKET, R.I.

CVS Pharmacy introduces new universal tools collection from one+other

Amazon

In the dynamic investment landscape, the spotlight often falls on the hottest sectors, attracting a swarm of investors. Yet savvy traders understand the attractiveness of value stocks which offer tremendous upside potential.

3 Value Stocks for Safe, Stable Portfolio Balance

CVS Health is trading at a significant discount, with its price-to-earnings valuation below its five-year average. CVS Health has diversified away from being a brick-and-mortar retailer, acquiring Aetna, Signify Health and Oak Street Health, which has not yet been fully recognized by investors. Despite an expected EPS decline of just over 1% in 2023, I believe CVS is undervalued with high financial flexibility and steady cash flow, making it a recommended long-term hold.

CVS Health: Undervalued Long-Term Gem

WOONSOCKET, R.I. , July 20, 2023 /PRNewswire/ -- CVS Health® Corporation (NYSE: CVS) has appointed J.

CVS Health appoints Scott Kirby to Board of Directors

Tandem Diabetes Care

CVS Health's broad array of healthcare services makes it an excellent long-term pick. Tandem Diabetes Care can still benefit from the vast untapped market within its niche.

2 Health Stocks Down 23% or More This Year That Could Rebound

Bank of America

Chubb

Bank of America should be well-positioned to deliver solid long-term returns. Chubb's underwriting expertise is its crown jewel.

3 Bargain Stocks You Can Buy Today and Hold Forever

Herbalife

Rite Aid

The Zacks Retail Pharmacy and Drugstore industry players like CVS, HLF and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.

News for CVS Health Stock (CVS)